Eli Lilly on Thursday said its daily obesity pill met the company's goals in the first of several late-stage trials, helping patients with Type 2 diabetes lower their blood sugar and body weight and ...
Eli Lilly reported a late-stage study of its oral weight-loss pill met primary and key secondary endpoints. The GLP-1 medication for obese or overweight patients with Type 2 diabetes lost an average ...
Eli Lilly said its daily obesity pill met the company's goals in the first of several closely watched late-stage trials. The pill helped Type 2 diabetes patients lower their blood sugar and body ...
Stream Connecticut News for free, 24/7, wherever you are. Eli Lilly on Thursday said its daily obesity pill met the company's goals in the first of several late-stage trials, helping patients with ...